IL-17 Receptor inhibition with brodalumab limits experimental periodontitis
Araceli Valverde, Raza Ali Naqvi, Matt Tokarski, Kristofer Ceredon, Joseph Gluck, Sarah Elshourbagy, Gloria Martínez, Maria Brambilla, Salvador Nares, Joel Schwartz, Afsar R Naqvi · 2026
Read IL-17 Receptor inhibition with brodalumab limits experimental periodontitis by Araceli Valverde, Raza Ali Naqvi, Matt Tokarski, Kristofer Ceredon, Joseph Gluck, Sarah Elshourbagy, Gloria Martínez, Maria Brambilla, Salvador Nares, Joel Schwartz, Afsar R Naqvi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13459357.txt.
Description
Valverde and colleagues tested in 2026 blocking the IL-17 receptor to calm periodontitis, the gum disease that destroys tissue and jaw bone. IL-17 is an immune signal family tied to this inflammation, and the receptor is a shared node for several family members, so blocking it could damp the whole pathway. The team profiled gum and saliva from healthy, diseased, and treated people, then gave the blocker brodalumab to mice with induced gum disease.
Valverde found IL-17-making T cells were raised in disease and fell after therapy, and gum biopsies confirmed the signal dropped with treatment. In mice, local injections of the blocker cut inflammatory gene messages in the gums. The main IL-17 signal was suppressed by day four and held down to day eight, and a second family signal fell too. Bone scans tracked jaw loss. The authors present receptor blockade as a candidate host-directed therapy.
Catalog record
| CREATOR | Araceli Valverde, Raza Ali Naqvi, Matt Tokarski, Kristofer Ceredon, Joseph Gluck, Sarah Elshourbagy, Gloria Martínez, Maria Brambilla, Salvador Nares, Joel Schwartz, Afsar R Naqvi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |